Pacritinib

4 trials 3 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

3 Sponsors

13 Countries

Phase III

Phase II

Phase III: 1 Phase II: 3

Indications tested

Myelofibrosis 2 VEXAS syndrome 1 Thrombocytopenia 1 Primary myelofibrosis 1

Sponsors using this IMP

Sobi Inc. 2 Grupo Espanol De Enfermedades Mieloproliferativas Cronicas Ph 1 Karyopharm Therapeutics Inc. 1

All trials

4 total

Pacritinib for Patients With Myelofibrosis Who Have Thrombocytopenia Recruiting

2025-522509-39-00 Phase II 1 country Grupo Espanol De Enfermedades Mieloproliferativas Cronicas Ph
A study to assess the effectiveness and safety of pacritinib in patients with VEXAS syndrome (PAXIS) Recruiting

2024-516347-41-00 Phase II 4 countries Sobi Inc.
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 Phase II 13 countries Karyopharm Therapeutics Inc.
PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro… Ended

2024-515953-52-00 Phase III 8 countries Sobi Inc.

Showing 1–4 of 4 trials

← All drugs A–Z